Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 51 - 100 out of 12,557

Document Document Title
WO/2020/131759A1
The present disclosure provides 3' protected nucleotides, including those 3' protected nucleotides having a detectable tag. Systems and methods of sequencing nucleic acids using the 3' protected nucleotides are also disclosed, such as th...  
WO/2020/123772A1
Solid forms of Compound I, which modulates the conversion of AMP to adenosine by 5'-nucleotidase, ecto, and compositions containing the compound and methods for preparing the solid forms, are described herein. The use of such solid form ...  
WO/2020/123488A1
The present disclosure provides crystalline Form II of nicotinic acid riboside, crystalline Form II of nicotinic acid riboside triacetate, and methods of preparation thereof. In an embodiment, the present disclosure relates to crystallin...  
WO/2020/122547A1
The present invention relates to a nicotinamide riboside derivative conjugated to a fatty alcohol, and a wrinkle reducing or anti-aging composition comprising same. A nicotinamide riboside derivative conjugated to a fatty alcohol accordi...  
WO/2020/117623A1
A class of polycyclic compounds of general formula (I), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2a, R3, R3a, R4, R5, R5a, R6, R6a, R7, R7a, R8, R8a, and R9 are defined herein, that may be useful as indu...  
WO/2020/117625A1
A class of polycyclic compounds of general formula (I), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2a, R3, R3a, R4, R4a, R5, R6, R6a, R7, R7a, R8, R8a, and R9 are defined herein, that may be useful as indu...  
WO/2020/118139A1
Disclosed are compounds of the formulas (I), (II), and (II): which are A1 adenosine receptor agonists, pharmaceutical compositions comprising such compounds, and a method of use of these compounds, wherein Y, R1‑R6, R10‑R15, and R20...  
WO/2020/117624A1
A class of polycyclic compounds of general formula (I), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2, R2a, R3a, R4, R5, R5a, R6, R6a, R7, R7a, R8, R8a, and R9 are defined herein, that may be useful as indu...  
WO/2020/108343A1
(I) An oral pharmaceutical composition containing a 4'-thionucleoside compound of formula (I), a capsule and a product containing same, and a preparation method therefor and the use thereof. The oral pharmaceutical composition has a good...  
WO/2020/104335A1
The present invention relates to a compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal...  
WO/2020/103929A1
Disclosed is an oligonucleotide and a prodrug thereof, and in particular, disclosed are: a compound shown by formula I, a tautomer thereof, a stereoisomer or a pharmaceutically acceptable salt thereof, a preparation method, a pharmaceuti...  
WO/2020/103916A1
Provided is a separation and purification method for uridine triphosphate. The separation and purification method comprises the following steps: 1) loading: filtering crude uridine triphosphate and then loading same into a chromatography...  
WO/2020/104492A1
The present invention relates to a method for preparing stereodefined phosphorothioate oligonucleotides, especially locked stereodefined phosphorothioate oligonucleotides with a high yield, using pyridinium acidic salts as a coupling act...  
WO/2020/107013A1
The disclosure includes compounds of Formula (I): wherein R1, R2, and R3, are defined herein. Also disclosed is a method for treating a neoplastic disease with these compounds.  
WO/2020/102980A1
Proposed is a preparation method for a nucleotide for sequencing, i.e. a preparation method for a compound represented by formula (I), comprising (1) performing a first nucleophilic substitution reaction on a compound represented by form...  
WO/2020/100826A1
The present invention provides a novel crosslinked artificial nucleic acid and an oligomer that includes the same as a monomer. More specifically, the present invention provides a compound represented by general formula (I) (the symbols ...  
WO/2020/102326A1
The present application provides methods for determining the level of NAD in a patient, including a whole blood sample from a patient. In addition, methods of increasing NAD levels in combination with determining the NAD level in a patie...  
WO/2020/085720A1
The present invention relates to a process for simultaneously preparing a lactic acid bacteria nucleotide and a low-molecular weight functional biomaterial having utility in industries related to skincare and cosmetics, and more specific...  
WO/2020/086366A1
The present disclosure provides methods for separating nucleic acids in a sample based on the length of the nucleic acids using a capillary electrophoresis device with formamide as a denaturing agent and a non-aqueous separation matrix c...  
WO/2020/086834A1
Disclosed herein, inter alia, are compounds, compositions, and methods of using the same for the sequencing of a nucleic acid.  
WO/2020/078807A1
The present invention relates to a prodrug compound of the general formula I or II. The prodrug compound of formula I or II is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3...  
WO/2020/078808A1
The present invention relates to a compound of the general formula I or II. The compound of formula I or II is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in ...  
WO/2020/081690A1
A compound has the following formula (I) or formula (II), an isomer thereof, a tautomer thereof, a pharmaceutical acceptable solvate thereof, or a pharmaceutical acceptable prodrug thereof.  
WO/2020/078000A1
1,3-disubstituted-2H-imidazolyl-2-carbene is a common type of azacyclocarbene, which may be used in a plurality of fields, comprising catalyzing organic reactions, acting as a transition metal ligand, and acting as a supporting ligand in...  
WO/2020/073274A1
Provided is a method for determining the sequence of a target single-chain polynucleotide, which method comprises monitoring the successive incorporation of nucleotides complementary to the target single-chain polynucleotide, wherein the...  
WO/2020/074004A1
Provided are a compound of formula (I), an optical isomer thereof, a pharmaceutically acceptable salt thereof, uses of said compoung acting as a STING agonist.  
WO/2020/072497A1
The invention provides a compound of formula (I): (I) wherein R is methyl or ethyl. The invention also provides a process for the preparation of the compound. The invention further provides a method for increasing cell NAD+ production or...  
WO/2020/073026A1
This disclosure provides a method of synthesis of 4'-thioribose NAD+ and analogues thereof, using an efficient chemoenzymatic approach. Also provided are methods of inhibiting the CD38 enzyme and compounds including 4'-thioribose NAD+ an...  
WO/2020/068657A1
Halogenated analogs of 5-aza-2'-deoxycytidine, such as halogenated analogs of 5-aza-4'-thio-2'-deoxycytidine (5-aza-T-dCyd) are described. Pharmaceutical compositions including a halogenated analog and methods of using the halogenated an...  
WO/2020/069424A1
The present disclosure provides methods of sequencing polynucleotides and compounds, compositions useful for sequencing of polynucleotides. The chemical compounds include nucleotides and their analogs which possess a sugar moiety compris...  
WO/2020/056713A1
A method for preparing high-purity NAD, comprising: adjusting a pH value to 6.0-8.0, removing insoluble substances, heating to 35 ± 1°C, adding ethanol, cooling to 6 ± 0.5°C, crystallizing, filtering, heating a filtrate to 25-30°C, ...  
WO/2020/057546A1
A cyclic dinucleotide analogue, a pharmaceutical composition thereof, and application. A cyclic dinucleotide analogue (I), an isomer thereof, a prodrug, a stable isotope derivative, or a pharmaceutically acceptable salt has the following...  
WO/2020/054444A1
[Problem] To develop a technique that can stabilize the higher-order structure of a nucleic acid and can be used in analysis of nucleic acid structure. [Solution] This guanosine derivative compound is represented by formula 1. In the for...  
WO/2020/055753A1
The post-translational modification (PTM) and signaling molecule poly(ADP-ribose) (PAR) has an impact on diverse biological processes. PTM is regulated by a series of ADP-ribosyl glycohydrolases (PARG enzymes) that cleave polymers and/or...  
WO/2020/051686A1
CD73 (also known as ecto-5 ' -nucleotidase) inhibitor compounds are provided, as well as compositions and uses thereof for treating or preventing CD73-associated or related diseases, disorders and conditions, including cancer- and immune...  
WO/2020/050411A1
The present invention provides a method for producing a glycoside compound represented by general formula (3), said glycoside compound enabling the synthesis of a desired compound (an amidite) with high purity. This method comprises a st...  
WO/2020/045628A1
The present invention addresses the problem of providing a nucleic acid analog, and a pharmaceutical composition, an anti-hepatitis virus agent and a preventive or therapeutic agent for a hepatitis virus-related disease each comprising a...  
WO/2020/047082A1
This application discloses CD73 inhibitors represented by the general formula (I) and analogs thereof, pharmaceutical compositions containing these compounds, methods of preparing them, and use of these compounds as therapeutic agents fo...  
WO/2020/042729A1
Disclosed are a 6-disulfide-substituted-2'-deoxyguanosine compound and a preparation method therefor and a use thereof in an anti-tumor drug. Using 2'-deoxyguanosine as a structure mother nucleus, the present invention designs and synthe...  
WO/2020/041051A1
Provided herein are phosphorylated gemcitabine derivative prodrug compounds, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of cancer.  
WO/2020/041050A1
Provided herein are phosphorylated gemcitabine derivative prodrug compounds, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of cancer.  
WO/2020/037275A1
Disclosed is a compound of formula (I), wherein Q, U, T, A, a, b, c, and n are as defined herein. Also disclosed are methods of inhibiting ecto‑5'‑nucleotidase, inhibiting suppression of an antitumor immune response, inhibiting tumor...  
WO/2020/036199A1
The present invention provides crystals of (1R,3R,15E,28R,29R,30R,31R,34R,36R,39S,41R)-29,41-Difluoro-3 4,39-bis(sulfanyl)-2,33,35,38,40,42-hexaoxa-4,6,9,11,13,18,2 0,22,25,27-decaaza-34λ5,39λ5-diphosphaoctacyclo[28.6.4.13, 36.128,31.0...  
WO/2020/032152A1
Current synthesis methods for 4'-substituted nucleoside derivatives include a step in which stereoisomers are produced and therefore have problems such as decreased yield and complication of a refinement step. Thus, a synthesis method ha...  
WO/2020/033624A1
The present disclosure is directed to methods of treating a disease associated with pathogenic B cells comprising administering to a subject in need thereof an effective amount of an Adora2A (adenosine A2A receptor) agonist. The method m...  
WO/2020/031131A1
The invention relates to compounds of Formulae (I), (Ia), (II) and (IIa), salts thereof, pharmaceutical compositions thereof, as well as methods of treating or preventing HIV in subjects.  
WO/2020/029647A1
Provided in the present invention is a method for synthesizing a nucleoside compound and an intermediate thereof, wherein the method is carried out by introducing a protective group at position 6 of guanine ketocarbonyl, causing only 9 N...  
WO/2020/028682A1
The present invention relates to amino acid salts of nicotinic acid and nicotinamide and compositions thereof of Formula I, useful in the treatment of disorders and diseases associated with deficiencies in NAD+: (I) wherein A, L, M1, M2,...  
WO/2020/026054A1
The compositions and compounds of formula I and formula II which includes nucleic acid synthesis inhibitor conjugates or its polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These conjugates may be formulated as ph...  
WO/2020/020208A1
The present application relates to a method for preparing trifluridine, comprising reacting a compound of formula III with a compound of formula IV in a first solvent in the presence of an acid to obtain a compound of formula II, and per...  

Matches 51 - 100 out of 12,557